Therapy with mycophenolate mofetil for refractory acute and chronic GVHD

Bone Marrow Transplantation

Volumn 44, Issue 11, 2009, Pages 739-748

  Furlong, T ^a   Martin, P ^a   Flowers, M E D ^a   Carnevale Schianca, F ^b   Yatscoff, R ^c   Chauncey, T ^a,d   Appelbaum, F R ^a   Deeg, H J ^a   Doney, K ^a   Witherspoon, R ^a   Storer, B ^a   Sullivan, K M ^e   Storb, R ^a   Nash, R A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF ALBERTA   (Canada)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute and chronic GVHD; HSCT; MMF

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DISEASE RESISTANCE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SURVIVAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75049084631     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.76     Document Type: Article

References (65)

1. Sullivan KM. Graft-versus-host disease. In: Blume KG, Forman SJ, Appelbaum FR, (eds). Thomas' Hematopoietic Cell Transplantation, 3rd edn. Blackwell Publishing Ltd: Malden, MA, 2004 pp. 635-664.
2. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
3. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
4. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962-968.
5. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593-602.
6. Martin PJ, McDonald GB, Sanders JE, Anasetti C, Appelbaum FR, Deeg HJ et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2004; 10: 320-327.
7. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76: 1464-1472.
8. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N et al. Treatment of moderate/severe acute graftversus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024-1030.
9. Hings IM, Severson R, Filipovich AH, Blazar BR, Kersey JH, Ramsay NKC et al. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation 1994; 58: 437-442.
10. MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NKC et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002; 8: 387-394.
11. Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy PL et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versushost disease: results of a randomized trial. Blood 2004; 104: 1559-1564.
12. Roy J, McGlave PB, Filipovich AH, Miller WJ, Blazar BR, Ramsay NK et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant 1992; 10: 77-82.
13. Martin PJ, Schoch G, Fisher L, Byers V, Appelbaum FR, McDonald GB et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991; 77: 1821-1828.
14. MacMillan ML, Weisdorf DJ, Davies SM, DeFor TE, Burns LJ, Ramsay NKC et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graftversus-host disease. Biol Blood Marrow Transplant 2002; 8: 40-46.
15. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C et al. Tumor necrosis factor-á blockade for the treatment of acute GVHD. Blood 2004; 104: 649-654.
16. Bolanos-Meade J, Jacobsohn DA, Margolis J, Ogden A, Guillaume Wientjes M, Boyd JC et al. Pentostatin in steroidrefractory acute graft-versus-host disease. J Clin Oncol 2005; 22: 2661-2668. (Pubitemid 46179455)
17. Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C et al. Safety and efficacy of denileukin diftitox in patients with steroid refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 1224-1226.
18. Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versushost disease. Blood 1994; 84: 1342-1348.
19. McCaul KG, Nevill TJ, Barnett MJ, Toze CL, Currie CJ, Sutherland HJ et al. Treatment of steroid-resistant acute graftversus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 2000; 9: 367-374.
20. Khoury H, Kashyap A, Adkins DR, Brown RA, Miller G, Vij R et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001; 27: 1059-1064.
21. Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002; 8: 155-160.
22. Lee SJ, Klein JP, Barnett J, Ringden O, Antin JH, Cahn JY et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406-414.
23. Goerner M, Gooley T, Flowers MED, Sullivan KM, Kiem HP, Sanders JE et al. Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. Biol Blood Marrow Transplant 2002; 8: 47-56.
24. Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004; 104: 3501-3506.
25. Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341: 14-21. (Pubitemid 29293715)
26. Lee WA, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990; 7: 161-166.
27. Eugui EM, Almquist SJ, Muller CD, Allison AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991; 33: 161-173.
28. Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. Transplant Proc 1991; 23(Suppl 2): 15-18.
29. Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991; 33: 175-183.
30. Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC. RS-61433-a new, potent immunosuppressive agent. Transplantation 1991; 51: 27-31.
31. Hao L, Lafferty KJ, Allison AC, Eugui EM. RS-61443 allows islet allografting and specific tolerance induction in adult mice. Transplant Proc 1990; 22: 876-879.
32. D'Alessandro AM, Rankin MA. Heterotopic rat intestinal transplantation: effect of cyclosporine and RS-61443 on graft-vs-host disease and rejection. Transplant Proc 1994; 26: 1611-1612.
33. Smit WM, Wagemans MAJ, Jansen CL, Horn GJVD, Surachno JS. Prevention of graft-versus-host disease by RS-61443 in two different rodent models. Transplantation 1993; 55: 221-223.
34. Yu C, Seidel K, Nash RA, Deeg HJ, Sandmaier BM, Barsoukov A et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 1998; 91: 2581-2587.
35. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325.
36. Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-232.
37. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037.
38. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996; 61: 722-729.
39. Basara N, Blau WI, Romer E, Rudolphi M, Bischoff M, Kirsten D et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998; 22: 61-65. (Pubitemid 28330537)
40. Takami A, Mochizuki K, Okumura H, Ito S, Suga Y, Yamazaki H et al. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. Int J Hematol 2006; 83: 80-85.
41. Baudard M, Vincent A, Moreau P, Kergueris MF, Harousseau JL, Milpied N. Graft-versus-host disease-mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 2002; 30: 287-295.
42. Busca A, Locatelli F, Marmont F, Audisio E, Falda M. Response to mycophenolate mofetil therapy for refractory chronic graft-versus-host disease. Haematologica 2003; 88: 837-839.
43. Lopez F, Parker P, Nademanee A, Rodriguez R, Al-Kadhimi Z, Bhatia R et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 307-313.
44. Soydan EA, Arat M, Topcuoglu P, Ozcan M, Arslan O, Idilman R et al. The effect of mycophenolate mofetil in steroid refractory or dependent chronic graft-versus-host disease. Bone Marrow Transplant 2003; 31 (Suppl 1): S135 (abstract P561).
45. Yusuf U, Sanders JE, Stephan V. Mycophenolate mofetil (MMF) as salvage treatment for steroid-refractory chronic graft-versus-host disease (GVHD) in children. Blood 2001; 98(Suppl 1): 398A (abstract 1672).
46. Abhyankar S, Godder K, Christiansen N, Chiang KY, DeRienzo S, O'Neal W et al. Treatment of resistant acute and chronic graft versus host disease with mycophenolate mofetil. Blood 1998; 92(Suppl 1): 340b (abstract 4467).
47. Kim JG, Sohn SK, Kim DH, Lee NY, Suh JS, Lee KS et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 2004; 73: 56-61.
48. Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 2005; 84: 681-685.
49. Langman LJ, LeGatt DF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity. Clin Chem 1995; 41: 295-299.
50. Przepiorka D, Weisdorf D, Martin PJ, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference of acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
51. Dugan MJ, Defor TE, Steinbuch M, Filipovich AH, Weisdorf DJ. ATG plus corticosteroid therapy for acute graft-versushost disease: predictors of response and survival (Review). Ann Hematol 1997; 75: 41-46.
52. MacMillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR et al. A phase 2/3 multicenter randomized trial of ABX-CBL versus ATG as secondary therapy for steroidresistant acute graft-versus-host disease. Blood 2007; 109: 2657-2662.
53. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I et al. Daclizumab, a humanized antiinterleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83-89.
54. Benito AI, Furlong T, Martin PJ, Anasetti C, Appelbaum FR, Doney K et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72: 1924-1929.
55. Jurado M, Vallejo C, Perez-Simon JA, Brunet S, Ferra C, Balsalobre P et al. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 701-706.
56. Parker PM, Chao N, Nademanee A, O'Donnell MR, Schmidt GM, Snyder DS et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86: 3604-3609.
57. Marcellus DC, Altomonte VL, Farmer ER, Horn TD, Freemer CS, Grant J et al. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. Blood 1999; 93: 66-70.
58. Seaton ED, Szydlo RM, Kanfer E, Apperley JF, Russell-Jones R. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood 2003; 102: 1217-1223.
59. Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Fili C et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007; 40: 273-277.
60. Martin PJ, Carpenter PA, Sanders JE, Flowers MED. Diagnosis and clinical management of chronic graft-versushost disease. Int J Hematol 2004; 79: 221-228.
61. Bornhauser M, Schuler U, Porksen G, Naumann R, Geissler G, Thiede C et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999; 67: 499-504.
62. Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005; 11: 495-505.
63. Kiehl MG, Shipkova M, Basara N, Blau IW, Schutz E, Armstrong VW et al. Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite. Clin Biochem 2000; 33: 203-208.
64. van Gelder T, Hilbrands LB, Yanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP et al. A randomized double-blind, multicenter plasma concentration conrolled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261-266.
65. Hale MD, Nicholls AJ, Bullingham RES, Hene R, Hoitsma A, Squifflet JP et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64: 672-683.